Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4077940
Max Phase: Preclinical
Molecular Formula: C29H34N4O7
Molecular Weight: 550.61
Molecule Type: Small molecule
Associated Items:
ID: ALA4077940
Max Phase: Preclinical
Molecular Formula: C29H34N4O7
Molecular Weight: 550.61
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)Oc1cc(C(=O)Nc2ccc(C(=O)Nc3ccc(C(=O)O)cc3OC(C)C)nc2OC(C)C)ccc1N
Standard InChI: InChI=1S/C29H34N4O7/c1-15(2)38-24-13-18(7-9-20(24)30)26(34)32-23-12-11-22(33-28(23)40-17(5)6)27(35)31-21-10-8-19(29(36)37)14-25(21)39-16(3)4/h7-17H,30H2,1-6H3,(H,31,35)(H,32,34)(H,36,37)
Standard InChI Key: CLABHIBFONXFKY-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 550.61 | Molecular Weight (Monoisotopic): 550.2427 | AlogP: 5.23 | #Rotatable Bonds: 11 |
Polar Surface Area: 162.10 | Molecular Species: ACID | HBA: 8 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 11 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.97 | CX Basic pKa: 2.73 | CX LogP: 4.35 | CX LogD: 1.40 |
Aromatic Rings: 3 | Heavy Atoms: 40 | QED Weighted: 0.23 | Np Likeness Score: -0.93 |
1. Yap JL, Chen L, Lanning ME, Fletcher S.. (2017) Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules., 60 (3): [PMID:27749061] [10.1021/acs.jmedchem.5b01888] |
2. Yang S, Mao Y, Zhang H, Xu Y, An J, Huang Z.. (2019) The chemical biology of apoptosis: Revisited after 17 years., 177 [PMID:31129454] [10.1016/j.ejmech.2019.05.019] |
3. Negi A, Murphy PV.. (2021) Development of Mcl-1 inhibitors for cancer therapy., 210 [PMID:33333396] [10.1016/j.ejmech.2020.113038] |
Source(1):